Skip to content

Sound Bioventures

Venture Capital Fund

  • CEO-Portal
  • Investor Portal
  • About
  • Team
  • Portfolio
  • Pipeline
  • Proposals
  • News
  • ESG
  • About
    • Team
    • Team Openings
    • Contact
    +
  • Portfolio
    • Aboleris
    • Artax Biopharma
    • Arthex
    • Breye Therapeutics
    • NephroDI
    • Teitur
    • Theolytics
    • VarmX
    +
  • Pipeline
  • Proposals
  • News
  • ESG
  • Press
  • Contact

Aboleris Pharma

All EventsFund articlesFund PRPortfolio articlesPortfolio PR

AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

2025.05.072025.05.07 / -Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- - ABO21009’s unique mechanism of action depletes pathogenic T and B ce ...

AbolerIS Pharma Announces Formation of Scientific Advisory Board

2025.04.292025.04.30 / Gosselies, Belgium and Nantes, France, April 24, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering fro ...

Bringing everything together for an autoimmunity game changer

2023.09.202024.05.13 / At AbolerIS Pharma, it's all about creating balance. The Belgian/French biotech company is gearing up for clinical trials of a novel therapy for stabilizing chaotic immune systems. As CEO Ann Meulema ...

AbolerIS Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases

2023.09.192024.05.13 / Financing round led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital. AbolerIS is developing a first-in-class drug inducing an immune tolerance-b ...
  1. Start
  2. News
  3. Aboleris Pharma

Sound Bioventures is a venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing novel medicines that addresses unmet medical needs.

Company

  • About
  • Team
  • Portfolio
  • Team Openings
  • News
  • Contact
  • Proposals

Contact & Press

  • Sustainability & SFDR
  • Privacy Policy
  • Subscribe to our newsletter
  • Press

Sound Bioventures Management AB
Org.no: 559310-0026
Nordenskiöldsgatan 11a
211 19 Malmö

Visiting address:
Sound Bioventures Management ApS
c/o Ordnung
Strandvejen 125
DK-2900 Hellerup, Denmark
Directions

Phone
+45 (0)60 - 63 31 20

General inquiries
info@soundbioventures.com

LinkedIn

© Copyright 2024 Sound Bioventures Management AB. All rights reserved. | We use cookies to improve our services

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all